The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
暂无分享,去创建一个
B. Korber | John P. Moore | Steven Wolinsky | T. Ketas | A. Marozsan | Joann M. Taylor | Pavel Pugach | John P Moore | Joann Taylor | Steven M Wolinsky | Shawn E Kuhmann | Amy Snyder | Bette T Korber | Andre J Marozsan | Thomas Ketas | S. Kuhmann | P. Pugach | Amy Snyder
[1] D. Ho,et al. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals , 1993, Journal of virology.
[2] Joseph Sodroski,et al. Association of Structural Changes in the V2 and V3 Loops of the gp120 Envelope Glycoprotein with Acquisition of Neutralization Resistance in a Simian-Human Immunodeficiency Virus Passaged In Vivo , 2000, Journal of Virology.
[3] A. Trkola,et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.
[4] C. Barbas,et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.
[5] J. Moore,et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.
[6] L. Stamatatos,et al. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. , 1998, AIDS research and human retroviruses.
[7] S. Matsushita,et al. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism. , 1997, AIDS research and human retroviruses.
[8] John P. Moore,et al. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. , 2004, AIDS research and human retroviruses.
[9] D. Ho,et al. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Doms,et al. A Replication-Competent, Neutralization-Sensitive Variant of Simian Immunodeficiency Virus Lacking 100 Amino Acids of Envelope , 2002, Journal of Virology.
[11] Q. Sattentau,et al. Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans , 1998, Journal of Virology.
[12] William C. Olson,et al. Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5 , 1999, Journal of Virology.
[13] A. Trkola,et al. Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization. , 1998, AIDS research and human retroviruses.
[14] M. Martin,et al. Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1 , 1994, Journal of virology.
[15] D. B. Anderson,et al. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression , 1999, Nature Medicine.
[16] N Bischofberger,et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. Koup,et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. , 1995, AIDS research and human retroviruses.
[18] B. Chesebro,et al. Immunodeficiency Virus Type 1 Macrophagetropic Isolates of Human Concentrations on Infections by Effects of CCR 5 and CD 4 Cell Surface , 1998 .
[19] Q. Sattentau,et al. Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding , 1990, The Journal of experimental medicine.
[20] K. E. Follis,et al. Continued Utilization of CCR5 Coreceptor by a Newly Derived T-Cell Line-Adapted Isolate of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[21] W. Blattner,et al. Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course , 2001, Journal of Virology.
[22] J. Moore,et al. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1 , 1996, Journal of virology.
[23] W A Hendrickson,et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. , 2000, Structure.
[24] K. Peden,et al. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1 , 1997, Journal of virology.
[25] J. Moore,et al. The HIV gp120-CD4 interaction: A target for pharmacological or immunological intervention? , 1993 .
[26] J. Harrison,et al. Expression of CCR5 Increases during Monocyte Differentiation and Directly Mediates Macrophage Susceptibility to Infection by Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[27] V. Hascall,et al. Cell surface heparan sulfate proteoglycans. , 1992, The Journal of biological chemistry.
[28] Paul W. H. I. Parren,et al. Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.
[29] M. Mulligan,et al. Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex. , 1992, Virology.
[30] J. Sodroski,et al. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein , 1997, Journal of virology.
[31] D. Dimitrov,et al. Multiple Interactions across the Surface of the gp120 Core Structure Determine the Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[32] M. Robb,et al. Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Resistance Is Associated with the Syncytium-Inducing Phenotype and Lower CD4 Cell Counts in Subtype CRF01_AE-Infected Patients , 2003, Journal of Virology.
[33] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Coffin. Genetic variation in AIDS viruses , 1986, Cell.
[35] D. Burton,et al. Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies , 2003, Journal of Virology.
[36] A. Trkola,et al. Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines , 1998, Journal of Virology.
[37] R. Doms. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. , 2000, Virology.
[38] D. Burton. Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.
[39] C. Spenlehauer,et al. Antibody-Mediated Neutralization of Primary Human Immunodeficiency Virus Type 1 Isolates: Investigation of the Mechanism of Inhibition , 2001, Journal of Virology.
[40] I. Chen,et al. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[41] Robyn L Stanfield,et al. Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor , 2004, Journal of Virology.
[42] J. Hansen,et al. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. , 1993, The Journal of general virology.
[43] R. Schooley,et al. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[44] R. Doms,et al. The entry of entry inhibitors: A fusion of science and medicine , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[45] Yoshiyuki Nagai,et al. Location-Specific, Unequal Contribution of the N Glycans in Simian Immunodeficiency Virus gp120 to Viral Infectivity and Removal of Multiple Glycans without Disturbing Infectivity , 1998, Journal of Virology.
[46] Joseph Sodroski,et al. Envelope Glycoprotein Determinants of Neutralization Resistance in a Simian-Human Immunodeficiency Virus (SHIV-HXBc2P 3.2) Derived by Passage in Monkeys , 2001, Journal of Virology.
[47] M. Reitz,et al. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene , 1988, Cell.
[48] J. Tse,et al. Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. , 1998, AIDS research and human retroviruses.
[49] R. Means,et al. A role for carbohydrates in immune evasion in AIDS , 1998, Nature Medicine.
[50] R. Means,et al. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus , 1997, Journal of virology.
[51] B. Cullen,et al. Molecular Basis for Cell Tropism of CXCR4-Dependent Human Immunodeficiency Virus Type 1 Isolates , 2001, Journal of Virology.
[52] E. Rieber,et al. Antibody and HIV-1 gpl20 recognition of CD4 undermines the concept of mimicry between antibodies and receptors , 1992, Nature.
[53] J. Hoxie,et al. Evidence that Antibody-Mediated Neutralization of Human Immunodeficiency Virus Type 1 by Sera from Infected Individuals Is Independent of Coreceptor Usage , 1998, Journal of Virology.
[54] John P. Moore,et al. Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site , 2003, Journal of Virology.
[55] D R Burton,et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.
[56] D. Montefiori,et al. Molecular Evolution of Human Immunodeficiency Virus env in Humans and Monkeys: Similar Patterns Occur during Natural Disease Progression or Rapid Virus Passage , 2002, Journal of Virology.
[57] H. Schuitemaker,et al. Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. , 2003, The Journal of infectious diseases.
[58] Peter D. Kwong,et al. The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.
[59] J. Moore,et al. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. , 1993, AIDS research and human retroviruses.
[60] J. Sodroski,et al. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.
[61] J. Sodroski,et al. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.
[62] Á. McKnight,et al. Cell surface receptors, virus entry and tropism of primate lentiviruses. , 2002, The Journal of general virology.
[63] J. Kilby,et al. Novel therapies based on mechanisms of HIV-1 cell entry. , 2003, The New England journal of medicine.
[64] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[65] A. Trkola,et al. Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage , 1998, Journal of Virology.
[66] John P. Moore,et al. New targets for inhibitors of HIV-1 replication , 2000, Nature Reviews Molecular Cell Biology.
[67] D. Kabat,et al. Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1. , 2000, AIDS research and human retroviruses.
[68] D. Burke,et al. Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic HIV in monocytes and T cells. , 1990, Journal of immunology.
[69] Chris Sander,et al. Globin fold in a bacterial toxin , 1993, Nature.
[70] H. Schuitemaker,et al. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera , 1995, Journal of virology.
[71] Q. Sattentau,et al. Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes , 1989, The Journal of experimental medicine.
[72] G. Melikyan,et al. Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion , 2000, The Journal of cell biology.
[73] J. Weber,et al. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. , 1991, BMJ.
[74] V. Hascall,et al. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. , 1993, AIDS research and human retroviruses.
[75] G. Quinnan,,et al. Both Neutralization Resistance and High Infectivity Phenotypes Are Caused by Mutations of Interacting Residues in the Human Immunodeficiency Virus Type 1 gp41 Leucine Zipper and the gp120 Receptor- and Coreceptor-Binding Domains , 1999, Journal of Virology.
[76] J. Hoxie,et al. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[77] J. Sodroski,et al. Neutralizing Antibodies in Sera from Macaques Infected with Chimeric Simian-Human Immunodeficiency Virus Containing the Envelope Glycoproteins of either a Laboratory-Adapted Variant or a Primary Isolate of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[78] John P. Moore,et al. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. , 2003, AIDS research and human retroviruses.
[79] R. F. Cook,et al. Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein , 1995, Journal of virology.
[80] Amanda M. Brown,et al. Selection for Neutralization Resistance of the Simian/Human Immunodeficiency Virus SHIVSF33A Variant In Vivo by Virtue of Sequence Changes in the Extracellular Envelope Glycoprotein That Modify N-Linked Glycosylation , 1999, Journal of Virology.
[81] J. McKeating,et al. Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization. , 1993, AIDS research and human retroviruses.
[82] Robert Blumenthal,et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[83] R. Desrosiers,et al. Importance of B-Cell Responses for Immunological Control of Variant Strains of Simian Immunodeficiency Virus , 2003, Journal of Virology.
[84] B. Chesebro,et al. Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[85] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.
[86] D. Weissman,et al. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[87] Susan Zolla-Pazner,et al. A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex , 2000, Journal of Virology.
[88] Serena Xu,et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[89] J. Moore,et al. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.
[90] H. Gendelman,et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.
[91] C. Broder,et al. UvA-DARE ( Digital Academic Repository ) Neutralizing antibodies to the HIV-1 envelope glycoproteins , 2009 .
[92] M. Bendinelli,et al. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system , 1994, Journal of virology.
[93] R. Desrosiers,et al. VIRAL PERSISTENCE: HIV's Strategies of Immune , 2002 .
[94] R. Doms,et al. Evaluation of current approaches to inhibit HIV entry. , 2002, Current drug targets. Infectious disorders.
[95] J. Sodroski,et al. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding , 1995, Journal of virology.
[96] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[97] J. Moore,et al. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 , 1997, Journal of virology.
[98] C. Cheng‐Mayer,et al. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization , 1994, Journal of virology.
[99] D R Burton,et al. gp120: Biologic aspects of structural features. , 2001, Annual review of immunology.
[100] Q. Sattentau,et al. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. , 1999, AIDS.
[101] J. Hansen,et al. Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance. , 1998, Scandinavian journal of infectious diseases.
[102] D R Burton,et al. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off , 1997, Journal of virology.
[103] D. Ho,et al. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[104] S. Zolla-Pazner,et al. Coreceptor Utilization by Human Immunodeficiency Virus Type 1 Is Not a Primary Determinant of Neutralization Sensitivity , 1998, Journal of Virology.
[105] J. Sodroski,et al. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.
[106] J. Moore,et al. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.
[107] W. James,et al. Cell-surface heparan sulfate facilitates human immunodeficiency virus Type 1 entry into some cell lines but not primary lymphocytes. , 1999, Virus research.
[108] S. Lewin,et al. Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages. , 1996, AIDS research and human retroviruses.
[109] J. Margolick,et al. Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.
[110] Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization , 1997, The Journal of experimental medicine.
[111] John P. Moore,et al. Inhibiting sexual transmission of HIV-1 infection , 2003, Nature Reviews Microbiology.
[112] A. Trkola,et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[113] J. Sodroski,et al. Envelope Glycoprotein Determinants of Increased Fusogenicity in a Pathogenic Simian-Human Immunodeficiency Virus (SHIV-KB9) Passaged In Vivo , 2000, Journal of Virology.